Reference

No. of patients

Dose

(mg/m²)

CR rates

(number)

Drug-related death rates (number)

Characteristics of AML patients

Time range

Sarah M. Larson [21]

78

ARA 3 g/m² daily for 2 days,

MXR 60 mg/m² daily for 2 days

45% (35)

9% (7)

High-risk

2001.5-2008.7

Marconi et al. [24]

55

MEC-6/5/4 for 1 or 2 course(s)

45.4% (25)¹ in the 1^st course

7.3% (4)

R/R

2009.1-2018.6

Franco Mandelli et al. [25]

2157

Cytarabine 25 mg/m² immediately followed by 100 mg/m² daily for 10 days plus etoposide 100 mg/m² daily for 5 days plus DNR 50 mg/m² or MXR 12 mg/m² or IDA 10 mg/m² daily on days 1, 3, 5.

DNR 68.7% (495/721),

MXR 69.8% (502/719),

IDA 66.9% (480/717)

DNR 8.9% (64),

MXR 10.0% (72),

IDA 10.3% (74)

NA

1993.11-1999.12

Löwenberg et al. [23]

489

DNR 30 mg/m² daily for 3 days or MTZ 8 mg/m² daily for 3 days, both plus ARA 100 mg/m² daily for 7 days (repeat in two cycles), followed by low-dose ARA 10 mg/m² daily

MTZ 46.6% (115/247), DNR 38% (92/242)

MTZ 21.1% (52/247), DNR 14.9% (36/242)

Elder people (median age of 68 years)

1986.4-1993.11